secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061271
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Q3 net loss $6.8M; TPST-1120 shows superiority in liver cancer; cash runway into 2025
--------------------------------------------------------------------------------

- Net loss $6.8M ($0.48/share) vs $8.9M ($0.66) in Q3 2022; R&D expense fell to $4.2M from $6.0M.
- Cash $11.1M at Sep 30; after $23.9M ATM net proceeds, preliminary cash $32.8M extending runway into 2025.
- TPST-1120 triplet arm cORR 30% vs 13.3% control; median PFS 7 mo vs 4.27 mo (HR 0.7); median OS not reached vs 15.1 mo (HR 0.59).
- Plan to advance TPST-1120 into registrational study in first-line HCC, likely with a partner.
- Adopted limited-duration stockholder rights plan on Oct 10, 2023 to deter hostile accumulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/0000950170-23-061271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017023061271/tpst-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer